Cuorips Inc.
Code | Sector | Market |
---|---|---|
4894 | Pharmaceuticals | Growth |
Date of listing approval | 2023/05/23 |
---|---|
Expected Date | 2023/06/27 |
Lead Underwriter | Nomura |
Description |
Listed Shares(total) | 2,530,000 |
---|---|
Trading Unit | 100 |
New Shares | 1,700,000 |
Existing Shares | 830,000¡Êincl. O.A.¡Ë |
Shares Outstanding | PreIPO 5,857,916.00 |
PostIPO 7,557,916.00 | |
Paid Up Capital | PreIPO Y104,150,000 |
PostIPO Y909,656,000 | |
Expected Pricing Date | 2023/06/08 |
Book Building Start | 2023/06/09 |
Book Building End | 2023/06/15 |
Fix Date | 2023/06/16 |
Offering Starts | 2023/06/19 |
Offering Ends | 2023/06/22 |
Expect Pricing | Y1,400-Y1,560 |
Notional PER (based on previous period) |
-21.02--23.42 |
Notional PER(based on results forecast) | -8.02--8.94 |
Offering Price | Y1,560 |
Offering Price PER (based on previous period) |
-8.02--8.94 |
Offering Price PBR (based on previous period) |
2.27 |
Offering Price PER (based on results forecast) |
-8.94 |
Use of Funds Raised |
Financial Data
Units:Y1,000
Fiscal Year End:2020/03 | ||
---|---|---|
Consolidated | Non-consolidated | |
Revenue | - | |
Current Profit | - | -176,987 |
Net Profit | - | -179,833 |
Net Assets | - | 750,177 |
Fiscal Year End:2021/03 | ||
---|---|---|
Consolidated | Non-consolidated | |
Revenue | - | 220 |
Current Profit | - | -295,845 |
Net Profit | - | -307,834 |
Net Assets | - | 4,222,342 |
Fiscal Year End:2022/03 | ||
---|---|---|
Consolidated | Non-consolidated | |
Revenue | - | 13,913 |
Current Profit | - | -373,140 |
Net Profit | - | -375,337 |
Net Assets | - | 3,895,546 |
Recent Quarter 2022/12 |
||
---|---|---|
Consolidated | Non-consolidated | |
Revenue | - | 13,488 |
Current Profit | - | -356,243 |
Net Profit | - | -357,352 |
Net Assets | - | 3,548,348 |
Results Forecast 2024/03 |
||
---|---|---|
Consolidated | Non-consolidated | |
Revenue | - | 215,000 |
Current Profit | - | -1,246,000 |
Net Profit | - | -1,249,000 |
Net Assets | - | - |
Per Share Units:Y1
Fiscal Year End:2020/03 | ||
---|---|---|
Consolidated | Non-consolidated | |
Dividend | 0.00 | |
Net Earning | - | - |
Equity | -97.31 | 407.24 |
Fiscal Year End:2021/03 | ||
---|---|---|
Consolidated | Non-consolidated | |
Dividend | 0.00 | |
Net Earning | - | - |
Equity | -123.65 | 751.03 |
Fiscal Year End:2022/03 | ||
---|---|---|
Consolidated | Non-consolidated | |
Dividend | 0.00 | |
Net Earning | - | - |
Equity | -66.60 | 686.19 |
Fiscal Year End:Recent Quarter 2022/12 |
||
---|---|---|
Consolidated | Non-consolidated | |
Dividend | ||
Net Earning | - | -63.16 |
Equity | - | - |
Fiscal Year End:Results Forecast 2024/03 |
||
---|---|---|
Consolidated | Non-consolidated | |
Dividend | 0.00 | |
Net Earning | - | -174.50 |
Equity | - | - |
Comment
¢£Over allotment(330,000) |
Consolidated Subsidiaries
Name | Address |
---|
Underwriters
Allocation | Underwriter | Tel |
---|---|---|
0% | Nomura | 03-3211-1811 |
92% | Nomura | 03-3211-1811 |
7.5% | SBI SECURITIES Co.,Ltd. | 03-5562-7210 |
0.5% | Matsui | 03-5216-0606 |
Data
Date of incorporation | 2017/03/21 |
---|---|
Company address | Tokyo 103-0023 |
Telephone | 03-6231-0043 |
President | |
Homepage | https://cuorips.co.jp/ |
Auditor | Azsa |
Major Shareholders | |
---|---|
Shareholder Name | Ratio |
86.62% | |
15.75% | |
9.13% | |
8.35% | |
7.87% | |
7.87% | |
7.87% | |
7.22% | |
6.30% | |
4.30% | |
3.40% |
Number of Employees | 46 as of 2023/04/30 |
---|---|
Birth Date of Representative | 1958/12/17 |